gemcabene has been researched along with Hyperlipoproteinemia Type II in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakker-Arkema, R; Bisgaier, C; Durst, R; Gaudet, D; Golden, L; Hegele, RA; Kastelein, JJ; Lepor, N; Masson, L; Stein, E | 1 |
| Ajufo, E; Rader, DJ | 1 |
1 review(s) available for gemcabene and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
New Therapeutic Approaches for Familial Hypercholesterolemia.
Topics: Angiopoietin-like Proteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Benzimidazoles; Caproates; Cholesterol Ester Transfer Proteins; Dicarboxylic Acids; Fatty Acids; Genetic Therapy; Humans; Hyperlipoproteinemia Type II; Oligonucleotides; Receptors, LDL; RNA, Small Interfering; Treatment Outcome | 2018 |
1 trial(s) available for gemcabene and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
Topics: Anticholesteremic Agents; Caproates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; Proprotein Convertase 9; Receptors, LDL; Survival Analysis; Time Factors; Treatment Outcome | 2019 |